Adimune™ has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases of the central nervous system (“CNS”) with the initial focus on the rare, but debilitating, autoimmune disease Stiff Person Syndrome. Adimune was founded earlier this year to lead Aditxt’s immune modulation therapeutic programs.